OClawVPS.com
Palette Life Sciences
Edit

Palette Life Sciences

http://www.palettelifesciences.com/
Last activity: 30.08.2023
Active
Categories: ServiceBuildingCultureHardwareHealthTechLEDLifeMedTechPageProduct
Palette Life Sciences is a fully-integrated medical device company focused on providing a wide range of products and services that improve the quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures.

We are a passionate team of individuals who enjoy the thrill of building a company whose culture is one of curiosity, compassion and drive. Looking for like-minded staff that has a complementary experience to add to the team. Our superior benefits package is proof positive that we care about our people.

Deflux® - the only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage.

Solesta® - the only FDA-approved injectable treatment for fecal incontinence, which is also cleared for commercialization in Europe. Fecal incontinence is a debilitating health problem afflicting about 2% of people worldwide with four times more prevalent in women than men.

Barrigel®* - a biodegradable injectable treatment for protection of the rectal wall when treating prostate cancer with radiation. The product is approved in Europe and will be further developed for future market introduction in the US.

Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California and Dallas, Texas. Learn more at palettelifesciences.com and pharmanest.se.

Deflux®, Solesta®, Barrigel®, Restylane®, and NASHA™ are registered trademarks.

*In the US, this product is considered investigational and not available for commercial sale in the US.
Mentions
21
Location: Sweden, Stockholm
Employees: 51-200
Total raised: $40M
Founded date: 2018

Investors 2

Funding Rounds 1

DateSeriesAmountInvestors
21.10.2021-$40M-

Mentions in press and media 21

DateTitleDescription
30.05.2023Palette Life Sciences Welcomes New Barrigel® Center of Excellence Program Designations/EIN News/ -- Recognizing exceptional leadership in patient education and clinical skill in the Barrigel procedure SANTA BARBARA, Calif. and STOCKHOLM, Sweden, May 30, 2023 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully-integrated globa...
09.02.2023Palette Life Sciences Announces Publication of Barrigel® Pivotal Safety and Efficacy Clinical Trial Data in JAMA OncologyRectal spacing with Barrigel® is proven safe and effective in improving rectal dosimetry and reducing acute Grade 2+ GI toxicity in first FDA-reviewed randomized controlled trial of rectal spacing using hypofractionated radiotherapy /EIN Ne...
09.02.2023Palette Life Sciences tillkännager publicering av Barrigel® Säkerhets- och effektdata i JAMA OncologyDen pivotala studien visar att separation av rektum och prostatan med Barrigel® är säkert och effektivt när det gäller att förbättra rektal dosimetri och minska akut toxicitet av grad 2+. Studien är den första FDA-granskade, randomiserade, ...
09.06.2022Palette Life Sciences tillkännager FDA godkännande av Barrigel®, en produkt som minimera skadliga och långvariga biverkningar från strålbehandling av prostatacancerBanbrytande teknologi minskar risken för strålskador i ändtarmen – bättre kontroll och optimerad lokalisering av stråldosen SANTA BARBARA, Calif. och STOCKHOLM, Sverige, June 09, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett globalt m...
09.06.2022Palette Life Sciences Announces FDA 510(k) Clearance for Barrigel® Rectal Spacer, Proven Safe and Effective at Minimizing the Harmful Long-Term Side Effects of Prostate Radiation TherapySANTA BARBARA, Calif. and STOCKHOLM, Sweden, June 09, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully-integrated global life sciences company dedicated to improving patient outcomes, today announced U.S. Food and Drug Administration...
29.03.2022Palette Life Sciences Receives Favorable Post Approval Study Results for Solesta®SANTA BARBARA, Calif. and STOCKHOLM, Sweden, March 29, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the results of their Solesta® Po...
24.02.2022Palette Life Sciences inleder ett samarbete med Lantheus för att marknadsföra PYLARIFY® (piflufolastat F-18)SANTA BARBARA, Calif. och STOCKHOLM, Sverige, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (”Palette”), ett globalt företag inom medicinteknik som arbetar för att förbättra behandlingsresultaten av bland annat strålbehandling av ...
24.02.2022Palette Life Sciences Enters Into an Agreement with Lantheus to Support the Promotion of PYLARIFY® (Piflufolastat F18)Partnership leverages Palette’s specialty sales team to increase promotional footprint of PYLARIFY within the urology call point SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (“Palette”...
15.02.2022Palette Life Sciences Announces the Establishment of a Wholly Owned Subsidiary in JapanExpansion will allow for Palette Life Sciences to provide better support to healthcare providers in Japanese market SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated glo...
15.02.2022Palette Life Sciences tillkännager bildandet av ett helägt dotterbolag i JapanUtvidgningen kommer att göra det möjligt för Palette Life Sciences att ge bättre stöd till vårdgivare på den japanska marknaden SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In